
The official account for the @CUMedicalSchool @CUAnschutz Lymphoma Program. #lymsm
Denver, CO
Joined September 2022
- Tweets596
- Following225
- Followers320
- Likes2.4K
Our @CUHematology website features all of our open B- and T-cell lymphoma and cellular therapy clinical trials, by Drs. @mana1981, @BradHaverkos, @StevenBairMD and @majorajay. #lymsm #clinicaltrials medschool.cuanschutz.edu/hem…
CU Anschutz Lymphoma Program retweeted
🚨Calling all mantle cell lymphoma clinicians🚨
redcap.link/MCLSurvey
Please take our quick <10 minute survey - 7 short management cases - we want to hear your treatment preferences!
You can answer as if able to access any therapy at any time. #ASH26 #lymsm
Our @CULymphoma lead Dr. @mana1981 and @CUInternalMed chief Dr. @vpizzuti44 contributed to a multicenter study on CAR-T vs ASCT in second-line PMBCL, now published @BloodAdvances. #lymsm #bmtsm ashpublications.org/bloodadv…
CU Anschutz Lymphoma Program retweeted
Love working with this diverse group of #lymsm clinician-scientists at @CUAnschutz @CUHematology!
We are looking forward to seeing you all at @ASH_hematology #ASH26.
cc @mana1981 @BradHaverkos @StevenBairMD @cduarte8490
It's been a busy year for our @CULymphoma faculty! Let's preview our abstracts and presentations at the upcoming @ASH_hematology #ASH26 Annual Meeting in December!
First, Dr. @mana1981 is giving a prestigious Education Program talk on non-T-cell engaging therapies for FL. #lymsm
It's been a busy year for our @CULymphoma faculty! Let's preview our abstracts and presentations at the upcoming @ASH_hematology #ASH26 Annual Meeting in December!
First, Dr. @mana1981 is giving a prestigious Education Program talk on non-T-cell engaging therapies for FL. #lymsm
Dr. @majorajay has several abstracts as part of the @SWOG Lymphoma Committee & the CUBIC Consortium, as well as posters on patient-reported outcomes in NLPHL and myeloma. He is also moderating an oral session (w/ @heMEGirl_MD) on toxicities & late effects after #lymsm treatment.
Our rare disease expert Dr. @cduarte8490 has several abstracts on #lymsm outcomes with bispecific antibodies, including a first-author abstract from the CUBIC Consortium and a senior-author abstract in rare LBCL histologies. #lymsm #ASH26
2
125
CU Anschutz Lymphoma Program retweeted
Great work by @majorajay adding yet another factor (time toxicity) helping clinicians on deciding between two very effective therapies in FL.
Excited to share our new @BloodPortfolio manuscript comparing CAR-T vs BsAb in R/R FL.
In addition to comparing survival, we also studied "time toxicity," or how much time patients spend physically interacting with the healthcare system. #lymsm 🧵
ashpublications.org/bloodadv…
CU Anschutz Lymphoma Program retweeted
Longer PFS, more days of care: the CAR T vs bispecifics trade-off in R/R FL. Retrospective, 228 pts, 17 US centers: median PFS NR vs ~19 mo, OS similar, yr-1 care contact days 58-69 vs 44-49. @majorajay @BloodPortfolio #lymsm #FollicularLymphoma doi.org/10.1182/bloodadvance…
CU Anschutz Lymphoma Program retweeted
Comparative survival and time toxicity outcomes of CAR-T versus bispecific antibody therapies in relapsed/refractory FL ashpublications.org/bloodadv… #lymsm
CU Anschutz Lymphoma Program retweeted
Establishing a benchmark to help physicians counsel patients with follicular lymphoma (FL) on the expected time toxicity associated with CAR T-cell therapy versus bispecific antibody (BiTE) therapy.
Full article link
doi.org/10.1182/bloodadvance…
Congratulations to our junior @CUHematology faculty on publication of this multicenter study comparing survival and time toxicity outcomes between CAR-T and bispecific antibodies in follicular lymphoma! #lymsm #tcellrx cc @BloodPortfolio @CUMedicalSchool @CUAnschutz
Excited to share our new @BloodPortfolio manuscript comparing CAR-T vs BsAb in R/R FL.
In addition to comparing survival, we also studied "time toxicity," or how much time patients spend physically interacting with the healthcare system. #lymsm 🧵
ashpublications.org/bloodadv…
CU Anschutz Lymphoma Program retweeted
Excited to share our new @BloodPortfolio manuscript comparing CAR-T vs BsAb in R/R FL.
In addition to comparing survival, we also studied "time toxicity," or how much time patients spend physically interacting with the healthcare system. #lymsm 🧵
ashpublications.org/bloodadv…
Our @CULymphoma lead Dr. @mana1981 just published a claims data analysis @BloodAdvances on CAR-T referral patterns in the United States. #lymsm #tcellrx pubmed.ncbi.nlm.nih.gov/4295…
Our T-cell lymphoma expert @CUAnschutz Dr. @BradHaverkos was interviewed on the @mghpetal #podcast about MRD monitoring in PTCL. #lymsm
YouTube: youtu.be/0OcU_FcZph4
Spotify: spotifycreators-web.app.link…
Apple: podcasts.apple.com/us/podcas…
On the PETAL Podcast, host @yumengzhang2009 of
@MoffittNews, discusses molecular residual disease monitoring in peripheral T-cell lymphoma with Dr. Brad Haverkos of @CUSystem.
🌸 Listen now: youtu.be/0OcU_FcZph4
Also available on Spotify & Apple Podcasts.
CU Anschutz Lymphoma Program retweeted
On the PETAL Podcast, host @yumengzhang2009 of
@MoffittNews, discusses molecular residual disease monitoring in peripheral T-cell lymphoma with Dr. Brad Haverkos of @CUSystem.
🌸 Listen now: youtu.be/0OcU_FcZph4
Also available on Spotify & Apple Podcasts.
CU Anschutz Lymphoma Program retweeted
Overseen by cardiologist Lavanya Kondapalli, MD, the University of Colorado Cardio-Oncology Program helps people with heart conditions undergoing treatment, as well as those who develop heart-related side effects from cancer therapies: bit.ly/4yu92Zc
Our @CUHematology lymphoma faculty Drs. @majorajay & @StevenBairMD contribute to the national CUBIC Consortium, with their latest publication on real-world outcomes of mosunetuzumab in indolent lymphomas now published @BloodPortfolio. #lymsm ashpublications.org/bloodneo…




























